AI gut-imaging software takes on the US with FDA clearance and national hospital partnership
Retrieved on:
Tuesday, November 23, 2021
Patient, Degenerative disease, Frimley Park Hospital, Irritable bowel syndrome, Movement, Radiological Society of North America, Magnetic resonance imaging, Technology, Crohn's disease, Nausea, AI, University College London Hospitals NHS Foundation Trust, RSNA, Comment, Hospital, NHS foundation trust, Partnership, European Society of Neurogastroenterology and Motility, Disease, King's College London, Federal Food, Drug, and Cosmetic Act, Liver, Abdominal pain, Physician, Radiology, Research, Pancreas, Decision-making, UCL, Frimley Health NHS Foundation Trust, Cost, University College London, MRI, HIV disease progression rates, Constipation, FDA, Great Ormond Street Hospital, Belle Taylor, Immunotherapy, Multimedia, Drug development, IBS, Quality of life, Medical device, Medical imaging, Animal
The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.
Key Points:
- The new FDA 510k clearance [search K211356] gives Motilent the greenlight to deploy GIQuant across healthcare providers in the US.
- Supporting the move into the US healthcare market, the company has also announced a new partnership with AI patient-care software provider Nuance.
- With FDA clearance, our first product GIQuant can be used in combination with routine MRI to easily evaluate gastrointestinal function.
- Peter Ellis, Chairman of Motilent says: "FDA clearance is an important step for Motilent as we move to the US market.